Project Grant R01CA301510
Award Date
4/15/25
Completion Date
3/31/28
Dollars Obligated
$793K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $213,284 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Beckman Research Institute of the City of Hope. The purpose of this 17-month grant, with an end date of April 30, 2025, is to determine the role of the CYP8B1 protein in obesity-associated hepatocellular carcinoma (HCC) and to develop novel CYP8B1 inhibitors as potential therapeutic candidates. The grant recipient, Beckman Research Institute, will conduct...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports an investigation into the role of metabolic stress and reprogramming in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC), the most common form of liver cancer. The $2,397,277 project, awarded on September 9, 2024, with a completion date of August 31, 2029, is being conducted by the Sanford Burnham Prebys Medical Discovery Institute. The project...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding research at the University of Illinois to investigate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and the development of hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH). The $599,299 award, with a start date of September 1, 2024 and end date of August 31, 2029, will validate the effect of HK2 on liver fibrosis and NASH-induced HCC...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $518,219 to the University of Pittsburgh to investigate the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a form of liver cancer. The key objectives are to: Examine the intertwined roles of the nuclear receptors FXR and CAR in promoting the transformation of hepatocytes into CCA cells within a cholestatic disease context. This will...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $687,679 to The Trustees of Columbia University in the City of New York to conduct research on understanding and targeting transcriptional master regulators in hepatocellular carcinoma (HCC). The key objectives are to: 1) computationally establish human HCC transcriptional master regulators (TMRs) and correlate them with clinical outcomes, 2) validate the tumor cell-intrinsic...
This Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to identify novel natural products that inhibit TEAD palmitoylation for the prevention and interception of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The $334,254 project, with a period of performance from May 2024 to April 2027, will be conducted by the University of Hawaii at Hilo. The research objectives...
This $1,224,644 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research at the Icahn School of Medicine at Mount Sinai to dissect the role of the immune checkpoint protein B7-H4 in promoting tumor growth and desmoplastic reactions in intrahepatic cholangiocarcinoma (CCA), a deadly form of liver cancer. The research aims to uncover the molecular mechanisms by which B7-H4 interacts with the TGF-beta pathway to shape the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $429,123 to Purdue University to develop improved inhibitors targeting the CBX8 chromodomain, a key component of chromatin regulation that is frequently dysregulated in cancer. The research aims to identify and optimize cell-permeable CBX8 inhibitors using DNA-encoded library screening and in vitro/in vivo testing to validate CBX8 as a viable therapeutic target, particularly...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $483,591 in funding to the University of California, Davis (UC Davis) to develop novel, biologic RNA molecules (BIORNAs) that can modulate hepatocellular carcinoma (HCC) metabolism. The key products and services to be delivered through this 5-year award include: (1) designing, cloning, expressing, and purifying a focused group of humanized BIORNAs for inhibiting...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer or hepatocellular carcinoma (HCC) during HIV infection. The research aims to understand how TAPDC reprogram the HCC tumor immune microenvironment, how TAPDC modulate anti-tumor T cells and enhance the cancer...